Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States

The development and widespread use of pneumococcal conjugate vaccines (PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the serotypes covered by PCVs may further reduce disease burden. A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Senders, Shelly, Klein, Nicola P., Lamberth, Erik, Thompson, Allison, Drozd, Jelena, Trammel, James, Peng, Yahong, Giardina, Peter C., Jansen, Kathrin U., Gruber, William C., Scott, Daniel A., Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Vaccine Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443440/
https://www.ncbi.nlm.nih.gov/pubmed/34525007
http://dx.doi.org/10.1097/INF.0000000000003277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443440/
https://www.ncbi.nlm.nih.gov/pubmed/34525007
http://dx.doi.org/10.1097/INF.0000000000003277

Ejemplares similares